Catalunya accelera el seu lideratge en salut i assoleix un nou rècord d’inversió en startups i scaleups - Parc Científic de Barcelona Les startups i scaleups del sector van aconseguir atreure 517 milions d’euros d’inversió, el volum més alt registrat fins ara.

#PCBCommunity |🚀 #Catalunya accelera el seu lideratge en #salut. L'informe de la #BioRegió 2025 de @biocat.cat mostra:

✅ 7,6% del PIB català
✅ 50.000 M€ de facturació
✅ 306.781 llocs de treball
✅ Les empreses van assolir 517 M€ d’inversió
✅ #SpliceBio (118M€) i #Deepull (50M€) encapçalen el ranking

#PCBCommunity |📢 #SpliceBio strengthens its leadership team with the appointment of Don Munoz as new #CFO. 💡He is a #biotechnology finance leader with experience in financial strategy, operations and corporate development with a strong background in #healthcare #investment banking.

👉 tuit.cat/tVf25

SpliceBio, awarded at the 2025 European LifeStars Awards - Parc Científic de Barcelona The company has been awarded at the 2025 European LifeStars Awards in the “Series B Raise of the Year” category.

#PCBCommunity |🏆 #SpliceBio has won the “Series B Raise of the Year” at the 2025 #EuropeanLifestarsAwards. 🚀 The recognition comes after they recently secured €118 million funding round, that will accelerate SB‑007, the company’s gene therapy for #Stargardt disease, a rare genetic retinal disorder.

📰 Entrevista a Miquel Vila-Perelló, cofundador de #SpliceBio, la companyia #biotecnològica que ha captat més diners en la història del sector de tot Espanya.

🔗 Llegeix l'entrevista completa al @ara.cat

Funding Raises: #Cyera $540M Series E; #AntaresTherapeutics $177M Series A; #Meter $170M Series C; #Glean $150M Series F; #SpliceBio $135M Series B; #GeckoRobotics $125M Series D; #Laurel $100M Series C; #Carbyne $100M Series D; #MuonSpace $89.5M Series B1; #Linear $82M Series C

SpliceBio gathers $135m for eye disease gene therapies Spain's SpliceBio has raised $135m in financing that will help it move a gene-editing therapy for Stargardt disease through clinical testing.

Spanish biotech #SpliceBio has raised $135 million in #financing that will help it move a #geneediting therapy for an inherited #retinaldisease through clinical testing.

#PortfolioNews | Proud to join the $135M Series B of our #portfolio company #SpliceBio, the largest round ever raised by a Spanish biotech 🚀

🧬 Advance SB-007 for #StargardtDisease
🔬Expand #GeneticMedicine pipeline

👉 buff.ly/jey8g9O

#VC #Biotech #Innovation #ProteinSplicing

#PCBCommunity |📢 #SpliceBio aixeca 118 M€ en la ronda més gran del sector biotecnològic a Espanya, liderada per EQT Life Sciences i Sanofi Ventures. 🔬La #startup destinarà els fons al desenvolupament clínic de la seva teràpia gènica SB-007 per a la malaltia de #Stargardt.

➕ info 👉 tuit.cat/6Ac83

EQT Life Sciences Secures $135 Million Series B Funding for SpliceBio's Innovative Gene Therapy EQT Life Sciences alongside Sanofi Ventures has co-led a successful $135 million funding round to advance SpliceBio's groundbreaking gene therapy technology, targeting genetic diseases effectively.

EQT Life Sciences Secures $135 Million Series B Funding for SpliceBio's Innovative Gene Therapy #Sweden #Stockholm #gene_therapy #EQT_Life_Sciences #SpliceBio

SpliceBio Raises $135 Million in Series B to Propel Genetic Medicine Innovations Against Stargardt Disease SpliceBio has secured $135 million in Series B financing to develop SB-007 for Stargardt disease and expand its pipeline of genetic therapies, enhancing treatments for complex genetic conditions.

SpliceBio Raises $135 Million in Series B to Propel Genetic Medicine Innovations Against Stargardt Disease #Spain #Barcelona #SpliceBio #SB-007 #Stargardt_Disease

#PCBCommunity |🌍 #Barcelona brilla al mapa #biotech! 🚀Les startups #NuageTherapeutics, #OnaTherapeutics i #SpliceBio, amb seu al PCB, han estat destacades per @natureportfolio.nature.com com a referents d’una nova generació d’empreses que lideren l’auge del sector a la ciutat.

➕ info👉 qrcd.org/8Xbg

#PCBCommunity |🔬 #SpliceBio administra la teràpia gènica SB-007 al primer pacient dins de l'assaig de fase 1/2 ASTRA per al tractament de la #MalaltiadeStargardt, un trastorn hereditari de la retina causat per mutacions al gen ABCA4, que provoca pèrdua de visió i #ceguesa 👁️

➕Més info👉 qrcd.org/8LiA

SpliceBio Secures FDA Approval for Innovative Stargardt Disease Treatment SB-007 SpliceBio's SB-007 has received FDA IND clearance, marking a breakthrough in treating Stargardt disease. This therapy targets the root cause of the condition across all mutations.

SpliceBio Secures FDA Approval for Innovative Stargardt Disease Treatment SB-007 #Spain #Barcelona #SpliceBio #SB-007 #Stargardt_Disease